1. Case Report: Neutralization of Autoantibodies Targeting G-Protein-Coupled Receptors Improves Capillary Impairment and Fatigue Symptoms After COVID-19 Infection
- Author
-
Friedrich E. Kruse, Thomas Prof. Harrer, Antonio Bergua, Michael Moritz, Andreas Gießl, Lennart Rogge, Felix Heltmann, Jakob Hoffmanns, Gerd Wallukat, Johannes Müller, Matthias Zenkel, Peter Göttel, Julia Schottenhamml, Annekathrin Haberland, Martin Herrmann, Martin Kräter, Robert Lämmer, Bettina Hohberger, Ursula Schlötzer-Schrehardt, Charlotte Szewczykowski, and Christian Y. Mardin
- Subjects
Drug ,Medicine (General) ,media_common.quotation_subject ,Glaucoma ,Case Report ,chronic fatigue syndrome ,Microcirculation ,R5-920 ,functional GPCR autoantibodies ,BC 007 ,medicine ,Chronic fatigue syndrome ,ddc:610 ,Respiratory system ,Receptor ,G protein-coupled receptor ,media_common ,long-COVID syndrome ,business.industry ,Autoantibody ,COVID-19 ,OCT angiography ,General Medicine ,medicine.disease ,glaucoma ,Immunology ,Medicine ,business - Abstract
Clinical features of Corona Virus Disease 2019 (COVID-19) are caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Acute infection management is a substantial health care issue, and the development of a Long-Covid syndrome (LCS) is extremely challenging for patients and physicians. It is associated with a variety of characteristics as e.g. impaired capillary microcirculation, chronic fatigue syndrome (CFS), pro-inflammatory cytokines, and functional autoantibodies targeting G-protein coupled receptors (GPCR-AAb). Here, we present a case report of a successful healing of LCS with BC 007 (Berlin Cures, Berlin, Germany), a DNA aptamer drug with high affinity to GPCR-AAbs that neutralizes these AAbs. A patient with a documented history of glaucoma, recovered from mild COVID-19, but still suffered from chronic fatigue syndrome, loss of taste and impaired capillary microcirculation in the macula and peripapillary region. He was positively tested for various targeting GPCR-AAbs. Within 48 h after a single BC 007 treatment, GPCR-AAbs were functionally inactivated and remained inactive during the observation period of 4 weeks. This observation was accompanied by a constant improvement of the patient’s fatigue symptoms, and taste as well as retinal capillary microcirculation. Therefore, it might be that removal of GPCR-AAb ameliorates characteristics of the Long-Covid-Syndrome such as capillary impairment, loss of taste and CFS.
- Published
- 2021
- Full Text
- View/download PDF